NNRTI (antiretroviral)

Doravirine

Brand names: Pifeltro

Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as part of combination antiretroviral therapy for HIV-1 infection.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds to and inhibits HIV-1 reverse transcriptase at an allosteric site, preventing conversion of viral RNA into DNA and so blocking replication.

Prescribing in practice

Strong cytochrome P450 3A inducers, such as rifampicin and certain anticonvulsants, substantially lower doravirine concentrations and are generally contraindicated or require regimen adjustment.
It is used only as part of a fully suppressive combination regimen, not as monotherapy.
Resistance can develop, so adherence is essential to maintain virological control.

Monitoring

Monitor HIV viral load and CD4 count to assess virological and immunological response during therapy.

Counselling the patient

Take the medicine every day as prescribed to keep the virus under control.
Tell your HIV team about all other medicines, as some can stop this drug working.

Evidence & guidelines

Doravirine-containing regimens are supported by randomised trials and are included as options in current HIV treatment guidelines.

Reference: BHIVA HIV guidelines; EACS; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

HIV CD4/Viral Load Monitoring Intervals · HIV Management

Drugs

Efavirenz · NNRTI (antiretroviral)

Pathways